Tristetraprolin regulates interleukin‐6, which is correlated with tumor progression in patients with head and neck squamous cell carcinoma
dc.contributor.author | Van Tubergen, Elizabeth | en_US |
dc.contributor.author | Vander Broek, Robert | en_US |
dc.contributor.author | Lee, Julia S. | en_US |
dc.contributor.author | Wolf, Gregory T. | en_US |
dc.contributor.author | Carey, Thomas | en_US |
dc.contributor.author | Bradford, Carol R. | en_US |
dc.contributor.author | Prince, Mark E. P. | en_US |
dc.contributor.author | Kirkwood, Keith L. | en_US |
dc.contributor.author | D'Silva, Nisha J. | en_US |
dc.date.accessioned | 2011-11-10T15:33:49Z | |
dc.date.available | 2012-07-12T17:42:24Z | en_US |
dc.date.issued | 2011-06-15 | en_US |
dc.identifier.citation | Van Tubergen, Elizabeth; Vander Broek, Robert; Lee, Julia; Wolf, Gregory; Carey, Thomas; Bradford, Carol; Prince, Mark; Kirkwood, Keith L.; D'Silva, Nisha J. (2011). "Tristetraprolin regulates interleukin‐6, which is correlated with tumor progression in patients with head and neck squamous cell carcinoma." Cancer 117(12): 2677-2689. <http://hdl.handle.net/2027.42/86915> | en_US |
dc.identifier.issn | 0008-543X | en_US |
dc.identifier.issn | 1097-0142 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/86915 | |
dc.description.abstract | BACKGROUND: Tumor‐derived cytokines play a significant role in the progression of head and neck squamous cell carcinoma (HNSCC). Targeting proteins, such as tristetraprolin (TTP), that regulate multiple inflammatory cytokines may inhibit the progression of HNSCC. However, TTP's role in cancer is poorly understood. The goal of the current study was to determine whether TTP regulates inflammatory cytokines in patients with HNSCC. METHODS: TTP messenger RNA (mRNA) and protein expression were determined by quantitative real‐time–polymerase chain reaction (Q‐RT‐PCR) and Western blot analysis, respectively. mRNA stability and cytokine secretion were evaluated by quantitative RT‐PCR and enzyme‐linked immunoadsorbent assay, respectively, after overexpression or knockdown of TTP in HNSCC. HNSCC tissue microarrays were immunostained for interleukin‐6 (IL‐6) and TTP. RESULTS: TTP expression in HNSCC cell lines was found to be inversely correlated with the secretion of IL‐6, vascular endothelial growth factor (VEGF), and prostaglandin E2 (PGE 2 ) . Knockdown of TTP increased mRNA stability and the secretion of cytokines. Conversely, overexpression of TTP in HNSCC cells led to decreased secretion of IL‐6, VEGF, and PGE 2 . Immunohistochemical staining of tissue microarrays for IL‐6 demonstrated that staining intensity is prognostic for poor disease‐specific survival ( P = .023), tumor recurrence and development of second primary tumors ( P = .014), and poor overall survival ( P = .019). CONCLUSIONS: The results of the current study demonstrated that down‐regulation of TTP in HNSCC enhances mRNA stability and promotes secretion of IL‐6, VEGF, and PGE 2 . Furthermore, high IL‐6 secretion in HNSCC tissue is a biomarker for poor prognosis. In as much as enhanced cytokine secretion is associated with poor prognosis, TTP may be a therapeutic target to reduce multiple cytokines concurrently in patients with HNSCC. Cancer 2011. © 2011 American Cancer Society. Tristetraprolin (TTP), a protein that decreases the stability of messenger RNA (mRNA) of cytokines and proinflammatory factors, is reduced in patients with head and neck squamous cell carcinoma with a corresponding increase in interleukin‐6 (IL‐6), vascular endothelial growth factor, and cyclooxygenase‐2 secretion. One of these tumor‐derived cytokines, IL‐6, is prognostic for poor disease‐specific survival, tumor recurrence, second primary lesions, and poor overall survival. | en_US |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Cytokines | en_US |
dc.subject.other | Interleukin‐6 (IL‐6) | en_US |
dc.subject.other | Vascular Endothelial Growth Factor (VEGF) | en_US |
dc.subject.other | Prostaglandin E2 (PGE2) | en_US |
dc.subject.other | Messenger RNA (MRNA) Stability | en_US |
dc.title | Tristetraprolin regulates interleukin‐6, which is correlated with tumor progression in patients with head and neck squamous cell carcinoma | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Otolaryngology, University of Michigan Medical School, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, 1011 N. University Avenue, Rm. 5217, Ann Arbor, MI 48109‐1078 | en_US |
dc.contributor.affiliationother | Department of Craniofacial Biology, The Medical University of South Carolina, Charleston, South Carolina | en_US |
dc.identifier.pmid | 21656745 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/86915/1/25859_ftp.pdf | |
dc.identifier.doi | 10.1002/cncr.25859 | en_US |
dc.identifier.source | Cancer | en_US |
dc.identifier.citedreference | Aggarwal BB, Gehlot P. Inflammation and cancer: how friendly is the relationship for cancer patients? Curr Opin Pharmacol. 2009; 9: 351 ‐ 369. | en_US |
dc.identifier.citedreference | Dong G, Loukinova E, Smith CW, Chen Z, Van Waes C. Genes differentially expressed with malignant transformation and metastatic tumor progression of murine squamous cell carcinoma. J Cell Biochem Suppl. 1997; 28‐29: 90 ‐ 100. | en_US |
dc.identifier.citedreference | Kanazawa T, Nishino H, Hasegawa M, et al. Interleukin‐6 directly influences proliferation and invasion potential of head and neck cancer cells. Eur Arch Otorhinolaryngol. 2007; 264: 815 ‐ 821. | en_US |
dc.identifier.citedreference | Chen Z, Malhotra PS, Thomas GR, et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res. 1999; 5: 1369 ‐ 1379. | en_US |
dc.identifier.citedreference | Pries R, Nitsch S, Wollenberg B. Role of cytokines in head and neck squamous cell carcinoma. Expert Rev Anticancer Ther. 2006; 6: 1195 ‐ 1203. | en_US |
dc.identifier.citedreference | Pries R, Wollenberg B. Cytokines in head and neck cancer. Cytokine Growth Factor Rev. 2006; 17: 141 ‐ 146. | en_US |
dc.identifier.citedreference | Singh B, Berry JA, Shoher A, Ramakrishnan V, Lucci A. COX‐2 overexpression increases motility and invasion of breast cancer cells. Int J Oncol. 2005; 26: 1393 ‐ 1399. | en_US |
dc.identifier.citedreference | Tsujii M, Kawano S, DuBois RN. Cyclooxygenase‐2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A. 1997; 94: 3336 ‐ 3340. | en_US |
dc.identifier.citedreference | Anderson P. Post‐transcriptional control of cytokine production. Nat Immunol. 2008; 9: 353 ‐ 359. | en_US |
dc.identifier.citedreference | Audic Y, Hartley RS. Post‐transcriptional regulation in cancer. Biol Cell. 2004; 96: 479 ‐ 498. | en_US |
dc.identifier.citedreference | Carrick DM, Blackshear PJ. Comparative expression of tristetraprolin (TTP) family member transcripts in normal human tissues and cancer cell lines. Arch Biochem Biophys. 2007; 462: 278 ‐ 285. | en_US |
dc.identifier.citedreference | Brennan SE, Kuwano Y, Alkharouf N, Blackshear PJ, Gorospe M, Wilson GM. The mRNA‐destabilizing protein tristetraprolin is suppressed in many cancers, altering tumorigenic phenotypes and patient prognosis. Cancer Res. 2009; 69: 5168 ‐ 5176. | en_US |
dc.identifier.citedreference | Young LE, Sanduja S, Bemis‐Standoli K, Pena EA, Price RL, Dixon DA. The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis. Gastroenterology. 2009; 136: 1669 ‐ 1679. | en_US |
dc.identifier.citedreference | Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001; 94: 153 ‐ 156. | en_US |
dc.identifier.citedreference | Riebe C, Pries R, Kemkers A, Wollenberg B. Increased cytokine secretion in head and neck cancer upon p38 mitogen‐activated protein kinase activation. Int J Mol Med. 2007; 20: 883 ‐ 887. | en_US |
dc.identifier.citedreference | Nystrom ML, McCulloch D, Weinreb PH, et al. Cyclooxygenase‐2 inhibition suppresses alphavbeta6 integrin‐dependent oral squamous carcinoma invasion. Cancer Res. 2006; 66: 10833 ‐ 10842. | en_US |
dc.identifier.citedreference | Peters WH, Lacko M, Te Morsche RH, Voogd AC, Oude Ophuis MB, Manni JJ. COX‐2 polymorphisms and the risk for head and neck cancer in white patients. Head Neck. 2009; 31: 938 ‐ 943. | en_US |
dc.identifier.citedreference | Sappayatosok K, Maneerat Y, Swasdison S, et al. Expression of pro‐inflammatory protein, iNOS, VEGF and COX‐2 in oral squamous cell carcinoma (OSCC), relationship with angiogenesis and their clinico‐pathological correlation. Med Oral Patol Oral Cir Bucal. 2009; 14: E319 ‐ E324. | en_US |
dc.identifier.citedreference | Kurihara Y, Hatori M, Ando Y, et al. Inhibition of cyclooxygenase‐2 suppresses the invasiveness of oral squamous cell carcinoma cell lines via down‐regulation of matrix metalloproteinase‐2 production and activation. Clin Exp Metastasis. 2009; 26: 425 ‐ 432. | en_US |
dc.identifier.citedreference | Egloff AM, Grandis JR. Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer. Semin Oncol. 2008; 35: 286 ‐ 297. | en_US |
dc.identifier.citedreference | Paul WE. Pleiotropy and redundancy: T cell‐derived lymphokines in the immune response. Cell. 1989; 57: 521 ‐ 524. | en_US |
dc.identifier.citedreference | Sok JC, Coppelli FM, Thomas SM, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res. 2006; 12: 5064 ‐ 5073. | en_US |
dc.identifier.citedreference | Mitra RS, Goto M, Lee JS, et al. Rap1GAP promotes invasion via induction of matrix metalloproteinase 9 secretion, which is associated with poor survival in low N‐stage squamous cell carcinoma. Cancer Res. 2008; 68: 3959 ‐ 3969. | en_US |
dc.identifier.citedreference | Mitra RS, Zhang Z, Henson BS, Kurnit DM, Carey TE, D'Silva NJ. Rap1A and rap1B ras‐family proteins are prominently expressed in the nucleus of squamous carcinomas: nuclear translocation of GTP‐bound active form. Oncogene. 2003; 22: 6243 ‐ 6256. | en_US |
dc.identifier.citedreference | Park NH, Min BM, Li SL, Huang MZ, Cherick HM, Doniger J. Immortalization of normal human oral keratinocytes with type 16 human papillomavirus. Carcinogenesis. 1991; 12: 1627 ‐ 1631. | en_US |
dc.identifier.citedreference | Patil CS, Liu M, Zhao W, et al. Targeting mRNA stability arrests inflammatory bone loss. Mol Ther. 2008; 16: 1657 ‐ 1664. | en_US |
dc.identifier.citedreference | Henson BS, Neubig RR, Jang I, et al. Galanin receptor 1 has anti‐proliferative effects in oral squamous cell carcinoma. J Biol Chem. 2005; 280: 22564 ‐ 22571. | en_US |
dc.identifier.citedreference | Goto M, Mitra RS, Liu M, et al. Rap1 stabilizes beta‐catenin and enhances beta‐catenin‐dependent transcription and invasion in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2010; 16: 65 ‐ 76. | en_US |
dc.identifier.citedreference | Gillenwater AM, Zhong M, Lotan R. Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells. Mol Cancer Ther. 2007; 6: 2967 ‐ 2975. | en_US |
dc.identifier.citedreference | Wolf GT, Urba S, Hazuka M. Induction chemotherapy for organ preservation in advanced squamous cell carcinoma of the oral cavity and oropharynx. Recent Results Cancer Res. 1994; 134: 133 ‐ 143. | en_US |
dc.identifier.citedreference | Ng DC, Long CS, Bogoyevitch MA. A role for the extracellular signal‐regulated kinase and p38 mitogen‐activated protein kinases in interleukin‐1 beta‐stimulated delayed signal tranducer and activator of transcription 3 activation, atrial natriuretic factor expression, and cardiac myocyte morphology. J Biol Chem. 2001; 276: 29490 ‐ 29498. | en_US |
dc.identifier.citedreference | Heidenreich O, Neininger A, Schratt G, et al. MAPKAP kinase 2 phosphorylates serum response factor in vitro and in vivo. J Biol Chem. 1999; 274: 14434 ‐ 14443. | en_US |
dc.identifier.citedreference | Winzen R, Kracht M, Ritter B, et al. The p38 MAP kinase pathway signals for cytokine‐induced mRNA stabilization via MAP kinase‐activated protein kinase 2 and an AU‐rich region‐targeted mechanism. EMBO J. 1999; 18: 4969 ‐ 4980. | en_US |
dc.identifier.citedreference | Brosens LA, Keller JJ, Pohjola L, et al. Increased expression of cytoplasmic HuR in familial adenomatous polyposis. Cancer Biol Ther. 2008; 7: 424 ‐ 427. | en_US |
dc.identifier.citedreference | Levy AP, Levy NS, Goldberg MA. Post‐transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem. 1996; 271: 2746 ‐ 2753. | en_US |
dc.identifier.citedreference | Hideshima T, Akiyama M, Hayashi T, et al. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood. 2003; 101: 703 ‐ 705. | en_US |
dc.identifier.citedreference | Druzgal CH, Chen Z, Yeh NT, et al. A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma. Head Neck. 2005; 27: 771 ‐ 784. | en_US |
dc.identifier.citedreference | Grunstein J, Roberts WG, Mathieu‐Costello O, Hanahan D, Johnson RS. Tumor‐derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res. 1999; 59: 1592 ‐ 1598. | en_US |
dc.identifier.citedreference | Bataille R, Barlogie B, Lu ZY, et al. Biologic effects of anti‐interleukin‐6 murine monoclonal antibody in advanced multiple myeloma. Blood. 1995; 86: 685 ‐ 691. | en_US |
dc.identifier.citedreference | Smith PC, Keller ET. Anti‐interleukin‐6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate. 2001; 48: 47 ‐ 53. | en_US |
dc.identifier.citedreference | Anderson P. Intrinsic mRNA stability helps compose the inflammatory symphony. Nat Immunol. 2009; 10: 233 ‐ 234. | en_US |
dc.identifier.citedreference | Stoecklin G, Stoeckle P, Lu M, Muehlemann O, Moroni C. Cellular mutants define a common mRNA degradation pathway targeting cytokine AU‐rich elements. RNA. 2001; 7: 1578 ‐ 1588. | en_US |
dc.identifier.citedreference | Taylor GA Carballo E Lee DM et al. A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity. 1996; 4: 445 ‐ 454. | en_US |
dc.identifier.citedreference | Lee HH Son YJ Lee WH et al. Tristetraprolin regulates expression of VEGF and tumorigenesis in human colon cancer. Int J Cancer. 2010; 126: 1817 ‐ 1827. | en_US |
dc.identifier.citedreference | Al‐Souhibani N Al‐Ahmadi W Hesketh JE Blackshear PJ Khabar KS The RNA‐binding zinc‐finger protein tristetraprolin regulates AU‐rich mRNAs involved in breast cancer‐related processes. Oncogene. 2010; 29: 4205 ‐ 4215. | en_US |
dc.identifier.citedreference | Keller ET Wanagat J Ershler WB Molecular and cellular biology of interleukin‐6 and its receptor. Front Biosci. 1996; 1: d340 ‐ d357. | en_US |
dc.identifier.citedreference | Kishimoto T. Interleukin‐6: from basic science to medicine–40 years in immunology. Annu Rev Immunol. 2005; 23: 1 ‐ 21. | en_US |
dc.identifier.citedreference | Duffy SA Taylor JM Terrell JE et al. Interleukin‐6 predicts recurrence and survival among head and neck cancer patients. Cancer. 2008; 113: 750 ‐ 757. | en_US |
dc.identifier.citedreference | De Schutter H Landuyt W Verbeken E Goethals L Hermans R Nuyts S. The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/− chemotherapy. BMC Cancer. 2005; 5: 42. | en_US |
dc.identifier.citedreference | Suswam E Li Y Zhang X et al. Tristetraprolin down‐regulates interleukin‐8 and vascular endothelial growth factor in malignant glioma cells. Cancer Res. 2008; 68: 674 ‐ 682. | en_US |
dc.identifier.citedreference | Basu A Datta D Zurakowski D Pal S. Altered VEGF mRNA stability following treatments with immunosuppressive agents: implications for cancer development. J Biol Chem. 2010; 285: 25196 ‐ 25202. | en_US |
dc.identifier.citedreference | Fantini MC Becker C Kiesslich R Neurath MF. Drug insight: novel small molecules and drugs for immunosuppression. Nat Clin Pract Gastroenterol Hepatol. 2006; 3: 633 ‐ 644. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.